Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ALEC vs ARVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALEC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

ALEC Overall Winner 6-Pillar Tally: ALEC 4 – 2 ARVN Matrix Metrics: ALEC 7 – 3 ARVN

As of Nov 16, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Arvinas, Inc (ARVN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ALEC carries a Unified Composite Score of 37.0/100 (SELL) at $2.54 (8.5x Forward P/E, 21.8% operating margin), whereas ARVN carries 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin).

  • Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. ALEC 37.0/100 SELL), ALEC captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.8% vs. -10.1% operating margin) and revenue trajectory (+4895.9% vs. -98.8% YoY).
  • Technical & Structure Timing Caution: ALEC trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALEC vs ARVN
ALEC NASDAQ Head-to-Head Winner
Alector, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.54
+0.2% 1D
Market Cap $364.7M
TTM Revenue $173M
Forward P/E 8.5x
Beta / 30D Vol 1.58β · 95% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 50.0 Fund 34.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 62.3 · SMA20: $2.21 · SMA50: $2.07
ARVN NASDAQ
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (ALEC 4 – 2 ARVN)

Columns: Metric · ALEC · ARVN
1. Valuation Multiples ALEC
Forward P/E 8.5x 17.9x
Trailing P/E 6.6x 17.9x
PEG Ratio N/M N/M
EV / Revenue 1.8x 1.3x
2. Growth & Scale ARVN
Revenue Growth (YoY) +4895.9% -98.8%
Earnings Growth (YoY) -86.3% +0.0%
TTM Revenue (USD) $173M $275M
Market Cap $364.7M $449.9M
3. Profitability & Quality ALEC
Gross Margin 42.5% 96.7%
Operating Margin 21.8% -10.1%
Net Profit Margin 23.9% -3.5%
Return on Equity (ROE) 47.5% -1.8%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$150M -$160M
Cash Flow Margin -86.5% -58.0%
Net Cash / Leverage $54M Net Cash $81M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ALEC
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 77.3% (9th %ile) 108.7% (25th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ALEC
OpEx & R&D Intensity 20.7% of Rev ($36M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALEC (7) vs ARVN (3)
Institutional Metric ALEC ARVN Criterion Row Edge
Market Capitalization
Scale
$364.7M $449.9M Larger Scale ARVN
Trailing P/E Ratio
Valuation
6.6x 17.9x Lower Multiple ALEC
Forward P/E Ratio
Valuation
8.5x 17.9x Lower Multiple ALEC
Revenue Growth (YoY)
Growth
+4895.9% -98.8% Higher Growth ALEC
Operating Margin (TTM)
Profitability
21.8% -10.1% Higher Margin ALEC
Net Profit Margin
Profitability
23.9% -3.5% Higher Margin ALEC
Return on Equity (ROE)
Capital Efficiency
47.5% -1.8% Higher ROE ALEC
52-Week Range Position
Momentum
83% ($1–$3) 5% ($6–$15) Stronger Trend ALEC
Beta / 30D Volatility
Risk Regime
1.58β · 95% Vol 1.40β · 66% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
37.0 / 100 (SELL) 52.9 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$173M $275M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.5% 96.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.8x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($54M Net Cash) -$160M ($81M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALEC +41.62 pp
ALEC: +38.32% · ARVN: -3.3%
3M Horizon ALEC +42.37 pp
ALEC: +15.16% · ARVN: -27.21%
6M Horizon ALEC +43.28 pp
ALEC: +20.05% · ARVN: -23.23%
1Y Horizon ALEC +145.48 pp
ALEC: +112.08% · ARVN: -33.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ALEC Revenue ARVN Revenue ALEC Op. Margin ARVN Op. Margin Margin Leader
FY2018 $30M $10M -208.3% -306.3% ALEC
FY2019 $20M $20M -539.2% -281.4% ARVN
FY2020 $20M $20M -925.1% -554.1% ARVN
FY2021 $210M $50M -18.0% -403.4% ALEC
FY2022 $130M $130M -103.2% -200.3% ALEC
FY2023 $100M $80M -156.3% -511.5% ALEC
FY2024 $100M $260M -144.2% -95.0% ARVN
FY2025 $20M $260M -741.3% -45.1% ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALEC CONSOLIDATION
52d in phase · OBV ACCUMULATION
Current IV 77.3%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ALEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALEC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $364.7M market capitalization and 21.8% operating margin.
OpEx & R&D Reinvestment 20.7% of Rev ($36M)
90D Engineering Disclosures 0 Published
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALEC vs ARVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Alector, Inc. (ALEC) is the stronger overall head-to-head candidate over Arvinas, Inc (ARVN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). ALEC carries a Unified Composite Score of 37.0/100 (SELL) at $2.54 (8.5x Forward P/E, 21.8% operating margin), whereas ARVN carries 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin). Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. ALEC 37.0/100 SELL), ALEC captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.8% vs. -10.1% operating margin) and revenue trajectory (+4895.9% vs. -98.8% YoY). Technical & Structure Timing Caution: ALEC trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.3); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARVN leads the Growth & Scale pillar: ALEC posts +4895.9% YoY revenue growth and -86.3% YoY earnings growth on $173M TTM revenue (42.5% gross margin, 21.8% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ALEC cumulative revenue shifted -33.3% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, ALEC deploys 20.7% of Rev ($36M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.

ALEC screens cheaper on headline valuation multiples. ALEC trades at 8.5x Forward P/E, 6.6x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (-86.5% FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALEC (47.5% ROE) versus ARVN (-1.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ALEC carries 77.3% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.58β · 95% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.